Navigation Links
Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
Date:10/23/2007

WALTHAM, Mass., Oct. 23 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC: ABOS) today announced that it has entered into an exclusive manufacturing agreement with NxStage Medical, Inc., whereby NxStage will manufacture the SEPET(TM) Liver Assist Device developed by Arbios for use in treating liver failure. Arbios is currently seeking permission from the US Food and Drug Administration to begin a controlled pivotal clinical trial for SEPET(TM).

Under the terms of the agreement, NxStage, a marketer of innovative systems for the treatment of end-stage renal disease and acute kidney failure, will manufacture the devices for the pivotal trial and subsequent product commercialization, upon receipt of FDA approval. The SEPET(TM) device will be comprised of commercially used NxStage components and will include a proprietary synthetic microporous fiber, supplied by Membrana, GmbH. Arbios, a developer of medical devices and cell-based therapies, recently announced an exclusive supply relationship with Membrana, which is the world's largest independent membrane producer.

"We are pleased to announce this exclusive arrangement with NxStage, as it signals another step in bringing SEPET(TM) to the marketplace," commented Shawn Cain, Interim President and Chief Executive Officer of Arbios. "This joint effort with NxStage, similar to the agreement recently entered into with Membrana, signifies another important alliance with an established and well- respected manufacturer of medical products."

"We are pleased to help bring innovative solutions to clinically challenging patients that need them," said Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "We believe that our technology and capabilities will enhance Arbios' opportunity and look forward to being a part of making them a success."

The exclusive manufacturing agreement stipulates that Arbios will purchase from NxStage all commercial requirements of the SEPET(TM) dev
'/>"/>

SOURCE Arbios Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... XI,AN, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical ... and producer of plant extracts and pharmaceutical raw ... is pleased to,announce record sales and earnings for ... 2008., "In the first half of 2008, ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... of novel drugs in the,therapeutic areas of infection, ... for the second quarter ended June 30, 2008., ... loss for the three months was $3.4 million ...
... 14 /PRNewswire-FirstCall/ - Ondine Biopharma,Corporation (the "Company" ... medical,technology company developing photodisinfection based products, today,announced ... ended June 30, 2008., "During the ... clinical,progress with our photodisinfection technology and we ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 4Advanced Life Sciences Announces Second Quarter 2008 Financial Results 5Advanced Life Sciences Announces Second Quarter 2008 Financial Results 6Advanced Life Sciences Announces Second Quarter 2008 Financial Results 7Advanced Life Sciences Announces Second Quarter 2008 Financial Results 8Advanced Life Sciences Announces Second Quarter 2008 Financial Results 9Advanced Life Sciences Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 2Ondine Biopharma Announces Second Quarter 2008 Financial Results 3Ondine Biopharma Announces Second Quarter 2008 Financial Results 4Ondine Biopharma Announces Second Quarter 2008 Financial Results 5Ondine Biopharma Announces Second Quarter 2008 Financial Results 6Ondine Biopharma Announces Second Quarter 2008 Financial Results 7Ondine Biopharma Announces Second Quarter 2008 Financial Results 8Ondine Biopharma Announces Second Quarter 2008 Financial Results 9Ondine Biopharma Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 11Ondine Biopharma Announces Second Quarter 2008 Financial Results 12Ondine Biopharma Announces Second Quarter 2008 Financial Results 13Ondine Biopharma Announces Second Quarter 2008 Financial Results 14Ondine Biopharma Announces Second Quarter 2008 Financial Results 15Ondine Biopharma Announces Second Quarter 2008 Financial Results 16Ondine Biopharma Announces Second Quarter 2008 Financial Results 17
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... high levels of vitamin D in their blood are more ... Patients with the highest levels of vitamin D have half ... levels, the findings reveal. , The study is the first ... cancer patients after their diagnosis which includes that produced ... with their long term survival prospects. , The ...
(Date:7/9/2014)... first make a copy of its DNA, a fundamental step ... times a day in the human body. While scientists have ... to replicate DNAthe enzymes that unzip the double-stranded DNA and ... how the process works. , Now, researchers at Rockefeller University ... on at the "replication fork"the point where DNA is split ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4
... studying the reliability of species distribution models for ... have focused their research on the endangered marsupial, ... Ecography demonstrates that studying weather events, rather ... a clearer insight into the Bettong,s movements, range ...
... BRUNSWICK, N.J. The National Institutes of Health (NIH) ... quick and economical analysis of tissue from breast cancer ... a common form of breast cancer is likely to ... minimize side effects. The NIH made its grant ...
... Large, persistent populations of genetically engineered canola ... North Dakota. As genetically engineered crops become increasingly ... potential ecological side effects. A study published ... reports that genetically engineered canola endowed with ...
Cached Biology News:Australia's endangered bettong reveals how weather effects species distribution 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 3